Scynexis (SCYX) Cash from Investing Activities (2013 - 2026)
Scynexis (SCYX) posted Cash from Investing Activities of -$525000.0 for Q1 2026, up 95.56% on a QoQ basis from -$11.8 million in Q4 2025, and down 104.22% year-over-year from $12.4 million in Q1 2025.
Scynexis (SCYX) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Scynexis' Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$525000.0 for Q1 2026.
- Quarterly Cash from Investing Activities fell 104.22% year-over-year to -$525000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (down 13.66% YoY) and the FY2025 annual result came in at $24.3 million, up 295.22% from the prior year.
- Cash from Investing Activities was -$525000.0 for Q1 2026 at Scynexis, up from -$11.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $12.4 million in Q1 2025 and bottomed at -$27.4 million in Q3 2022.
- A 5-year average of -$2.3 million and a median of -$267000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 8000.59% — and 2025, when it surged 721.65%.
- Scynexis' Cash from Investing Activities stood at -$27.4 million in 2022, then jumped by 92.14% to -$2.2 million in 2023, then fell by 21.61% to -$2.6 million in 2024, then sank by 351.82% to -$11.8 million in 2025, then soared by 95.56% to -$525000.0 in 2026.
- Business Quant data shows SCYX's Cash from Investing Activities at -$525000.0 in Q1 2026, -$11.8 million in Q4 2025, and $12.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.82 Bn | 87.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.03 Bn | 32.29 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.50 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.02 Bn | 20.86 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.43 Bn | 18.63 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.73 Bn | 12.30 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Scynexis | 23.19 Mn | -13.57 Mn | - | -525,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -525,000.00 |
| Mar 31, 2026 | -525,000.00 |
| Dec 31, 2025 | -11.82 Mn |
| Dec 31, 2025 | -11.82 Mn |
| Sep 30, 2025 | 12.42 Mn |
| Sep 30, 2025 | 12.42 Mn |
| Jun 30, 2025 | 11.27 Mn |
| Jun 30, 2025 | 11.27 Mn |
| Mar 31, 2025 | 12.44 Mn |
| Mar 31, 2025 | 12.44 Mn |
| Dec 31, 2024 | -2.62 Mn |
| Dec 31, 2024 | -2.62 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 5.45 Mn |
| Mar 31, 2024 | 5.45 Mn |
| Dec 31, 2023 | -2.15 Mn |
| Dec 31, 2023 | -2.15 Mn |